Welcome to our dedicated page for Dogwood Therapeutics news (Ticker: DWTX), a resource for investors and traders seeking the latest updates and insights on Dogwood Therapeutics stock.
Dogwood Therapeutics develops new medicines for pain and neuropathic disorders as a development-stage biopharmaceutical company listed on Nasdaq under DWTX. Company news centers on its pain and neuropathy pipeline, including Halneuron®, a non-opioid NaV 1.7 analgesic in development for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist program for chemotherapy-related pain and neuropathy.
Recurring updates also cover clinical and regulatory developments, FDA designations and investigational-drug activity, intellectual-property work tied to synthetic Halneuron®, financial results, financing activity, shareholder communications, and licensing arrangements involving anti-viral assets such as IMC-1 and IMC-2.
Dogwood Therapeutics (NASDAQ:DWTX) began a 12-week open-label Phase 2b extension study of Halneuron for chemotherapy induced neuropathic pain (CINP). The trial follows a positive interim assessment of a 4-week double-blind study and will collect additional safety and efficacy data.
Interim analysis based on 97 patients supported continuing the Phase 2b trial with a 210–240 patient sample to achieve 80% power. Top-line Phase 2b results are expected in fall 2026, with a Phase 3 program projected to start in the first half of 2027.
Dogwood Therapeutics (Nasdaq:DWTX) reported Q1 2026 results and pipeline progress. The Halneuron® Phase 2b CINP trial has enrolled 164 patients, with top-line data expected in fall 2026. SP16 received FDA IND clearance for a fully NCI-funded Phase 1b CIPPN trial.
The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100M. Q1 2026 R&D expenses were $2.7M and G&A $2.4M. Net loss was $5.0M ($0.15/share). Cash of $13.2M is expected to fund operations into Q4 2026.
Dogwood Therapeutics (Nasdaq: DWTX) will report its first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. Investors can expect a standard quarterly release and any accompanying investor materials or conference information to be shared around that time.
Dogwood Therapeutics (NASDAQ: DWTX) entered a global development and commercialization partnership with PRIDCor for antiviral candidates IMC-1 and IMC-2 dated April 23, 2026. PRIDCor will finance development; Dogwood is entitled to a tiered royalty up to 15%, 9% of future PRIDCor capital for these assets, and potential payments capped at $100 million. Dogwood will focus internally on Halneuron and SP16. Payments that qualify as CVR-related will be passed to CVR holders as required.
Dogwood Therapeutics (NASDAQ: DWTX) announced FDA acceptance of an IND for SP16, an IV candidate to treat chemotherapy-induced pain and peripheral neuropathy (CIPPN). Serpin Pharma is regulatory sponsor; a $2.5 million NCI grant will fully fund the planned Phase 1b trial, with enrollment expected mid-2026.
Dogwood holds a royalty-free global license to Serpin’s IV SP16 formulation acquired in September 2025.
Dogwood Therapeutics (Nasdaq: DWTX) reported Q4 and full-year 2025 results and clinical updates. Key items: interim Phase 2b analysis showed Halneuron® separating from placebo in a 97-patient subset; 143 patients recruited; trial >50% enrolled with top-line data expected in Q3 2026. The company completed a financing of up to $26.9M, receiving $12.5M gross and $11.4M net in Jan 2026, and had $6.5M cash at Dec 31, 2025, expected to fund operations into Q4 2026.
Full-year R&D rose to $21.8M vs $3.5M in 2024; net loss was $35.5M or $7.13 per share.
Dogwood Therapeutics (Nasdaq: DWTX) announced it has reached over 50% enrollment in the HALT-CINP Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain and remains on track for top-line results in Q3 2026.
An independent review of an earlier interim cohort reported separation from placebo on pain improvement and a low overall dropout rate (~4%). The randomized trial enrolls at ~30 U.S. sites with a 28-day follow-up and primary endpoint at week four.
Dogwood Therapeutics (NASDAQ: DWTX) announced registered and private offerings to raise up to $12.5 million in upfront gross proceeds and the potential for an additional $14.4 million upon warrant exercises, for aggregate financings tied to issuance of 4,386,037 common shares (or pre-funded warrants) and detachable warrants. Securities are priced at-the-market under Nasdaq rules at a combined purchase price of $2.85 and warrant exercise price of $3.28. Proceeds are earmarked to advance Halneuron through Phase 2b final readout and support further development and working capital.
Dogwood Therapeutics (Nasdaq: DWTX) reported a positive interim analysis from 97 patients in its Phase 2b study of Halneuron for chemotherapy induced neuropathic pain (CINP) on Dec 22, 2025. An independent committee found Halneuron-treated patients separated from placebo on pain improvement over four weeks. The company projects top-line results in Q3 2026 and enrollment trends that provide ~80%–85% statistical power. The interim cohort had an average CINP duration of 5 years, with 67% on stable background pain meds; overall dropout was ~4.4%. The company says safety and tolerability remain encouraging, and positive Phase 2b outcomes could support a Phase 3 registration program.
Dogwood Therapeutics (Nasdaq: DWTX) filed a new composition of matter intellectual property application for a fully synthetically manufactured Halneuron® on December 2, 2025. The company says the synthetic process delivers higher manufacturing yields and lower costs versus naturally harvested Halneuron® and is planned for use in Phase 3 development and commercialization. If the IP is granted, Dogwood projects the exclusivity period could extend to 2045, before any additional patent term restoration.